Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors

por Hoffman, Justin, Chakrabarti, Jayeta, Plotka, Anna, Milillo Naraine, Adriana, Kanamori, David, Moroose, Rebecca, Nguyen, Linh, Wang, Diane, Wainberg, Zev A.
Publicado 2019

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors

por Durairaj, Chandrasekar, Chakrabarti, Jayeta, Ferrario, Cristiano, Hirte, Holger W., Babu, Sunil, Piha-Paul, Sarina A., Plotka, Anna, Hoffman, Justin, Shi, Haihong, Wang, Diane D.
Publicado 2021

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment

por Guo, Cen, Yu, Yanke, Chakrabarti, Jayeta, Piha‐Paul, Sarina A., Moroose, Rebecca, Plotka, Anna, Shi, Haihong, Durairaj, Chandrasekar, Wang, Diane D., Wainberg, Zev A.
Publicado 2022

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

por Litton, Jennifer K, Beck, J Thaddeus, Jones, Jason M, Andersen, Jay, Blum, Joanne L, Mina, Lida A, Brig, Raymond, Danso, Michael, Yuan, Yuan, Abbattista, Antonello, Noonan, Kay, Niyazov, Alexander, Chakrabarti, Jayeta, Czibere, Akos, Symmans, William F, Telli, Melinda L
Publicado 2023

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

por Hurvitz, Sara A., Gonçalves, Anthony, Rugo, Hope S., Lee, Kyung‐Hun, Fehrenbacher, Louis, Mina, Lida A., Diab, Sami, Blum, Joanne L., Chakrabarti, Jayeta, Elmeliegy, Mohamed, DeAnnuntis, Liza, Gauthier, Eric, Czibere, Akos, Tudor, Iulia Cristina, Quek, Ruben G.W., Litton, Jennifer K., Ettl, Johannes
Publicado 2019